The debate proposed that Aβ-induced tau missorting creates self-sustaining toxicity, but didn't resolve whether this state is truly Aβ-independent once established. This is critical for understanding why anti-Aβ therapies fail and whether tau-targeting must follow specific temporal windows.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974)
Aβ initiates tau missorting, but persistent degeneration is then maintained by activated microglia through C1q/C3-CR3-mediated pruning and inflammatory remodeling. This model best explains continued synapse loss after amyloid reduction, though it may maintain degeneration more clearly than tau polarity failure itself.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C1Q Deficiency Impaired Clearance of Apoptotic Cells"]
B["C1QC Assembly Heterocomplex Formation"]
C["Synaptic Pruning Dysregulation Unpruned Connections"]
D["Microglial Overactivation Complement Deposition"]
E["C3b/C4b Deposition Neuronal Surface"]
F["Synaptic Loss Excessive Pruning in AD"]
G["Long-Term Potentiation Memory Formation Impaired"]
H["Cognitive Decline AD-Related Dementia"]
A --> B
B --> C
B --> D
C --> F
D --> E
E --> F
F --> G
G --> H
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Microglia-mediated synapse loss is strongly implic…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Title: Fyn-anchored dendritic tau becomes self-sustaining after transient Aβ exposure
Mechanism: Aβ oligomers drive tau missorting from axon to dendritic spines, where tau binds FYN and stabilizes an NMDA receptor-associated excitotoxic signaling complex. Once established, this tau-Fyn-PSD95/NMDAR scaffold may persist without continued Aβ, maintaining calcium dysregulation, spine loss, and downstream degeneration.
Target gene/protein/pathway:MAPT (tau), FYN, PSD95/DLG4, NMDAR/SRC-family signalingSupporting evidence: Strong prior literature links dendritic tau
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Below the central skeptical point applies to all seven: current literature strongly supports that Aβ can induce dendritic/somatodendritic tau missorting and synaptic toxicity, but it does not cleanly establish that the state becomes truly Aβ-independent after complete Aβ removal. Most cited evidence is either acute Aβ exposure, constitutive transgenic overexpression, or end-stage human tissue, which cannot separate “self-sustaining tau pathology” from “residual upstream injury,” incomplete Aβ clearance, or generic degeneration.
**Fyn-anchored dendritic tau self-sustains after transient
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Most investable survivors are `6 > 4 > 1 > 2`. I would not spend serious translational budget yet on `7`, and I would treat `3` and `5` as modifier mechanisms rather than lead programs.
| Rank | Hypothesis | Druggability | Biomarkers | Best model systems | Safety / translational risk | Realistic path | |---|---|---|---|---|---|---| | 1 | `6` Tau missorting transitions into autonomous tau seeding | High, relative to others. Clear intervention classes: anti-tau antibodies, seed-blocking biologics, ASOs, uptake blockers. | CSF/plasma p-tau217, p-tau181, MTBR-tau, tau seeding assays, tau PET, syn
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Tau missorting transitions into an autonomous tau-seeding state after transient Aβ exposure","description":"Transient Aβ exposure induces dendritic tau missorting that then converts into a locally self-propagating tau oligomer/seeding program. After verified Aβ clearance, continued degeneration is driven by tau seed formation, templated misfolding, and trans-synaptic spread rather than by ongoing amyloid signaling.","target_gene":"MAPT","dimension_scores":{"evidence_strength":0.78,"novelty":0.72,"feasibility":0.83,"therapeutic_potential":0.84,"mechanistic_plausi
IF C1q/C3-CR3-mediated microglial pruning sustains synapse loss after tau missorting is established, THEN pharmacologically blocking CR3 (ITGAM) with a selective antagonist 3 months after Aβ42 oligomer injection in 5xFAD mice will significantly reduce hippocampal synapse loss compared to vehicle controls within 8 weeks of treatment.
pendingconf: 0.65
Expected outcome: Hippocampal CA1 synapse density will increase by ≥25% (measured by PSD95+VGluT1 colocalization via confocal microscopy) in CR3-blocked mice relative to vehicle-treated controls at 5 months post-Aβ42 injection.
Falsified by: No statistically significant difference in synapse density between CR3-blocked and vehicle groups (p>0.05, Mann-Whitney U test), indicating that blocking complement-mediated pruning does not halt post-tau-missorting neurodegeneration.
Method: 5xFAD transgenic mice (n≥12/group) receiving stereotactic hippocampal injection of Aβ42 oligomers at 2 months, followed by intraperitoneal CR3 antagonist (or vehicle) starting at 5 months, with endpoint analysis at 6 months using quantitative neuroanatomy.
IF microglia activation is the obligate maintenance mechanism for post-Aβ neurodegeneration independent of tau polarity failure, THEN conditional knockout of TREM2/TYROBP specifically after tau missorting onset (via tamoxifen-inducible CreERT2 system) will arrest neurodegeneration progression in P301S;TREM2-cKO mice, whereas neurodegeneration will continue unabated in P301S;TREM2-WT littermates.
pendingconf: 0.58
Expected outcome: CSF neurofilament light chain (NfL) levels will stabilize (change <5%/month) in P301S;TREM2-cKO mice after tamoxifen-induced knockout, while P301S;TREM2-WT mice will show continued NfL increase (≥10%/month) over 6 months of observation.
Falsified by: Equivalent rates of NfL increase in both TREM2-cKO and TREM2-WT groups (overlapping 95% CIs), indicating that removing microglial TREM2 signaling does not interrupt neurodegeneration progression despite tau pathology.
Method: Tamoxifen-inducible P301S;Trem2-flox/flox mice crossed with Rosa26-CreERT2 (n≥15/group), receiving tamoxifen at 4 months (when tau missorting is established by PET), with monthly CSF sampling for NfL quantification and longitudinal MEMRI atrophy tracking.